SAN DIEGO, CA , March 5, 2019 – Multimeric Biotherapeutics, Inc., a biotechnology company developing vaccines against cancer and infectious diseases, announced today that it has been accepted to present at the Immunology 2019 meeting to be held in San Diego, CA. The title of the Company’s abstract is “CD40 ligand (CD40L) multi- trimer antigen fusion protein (FortiVacTM) as a vaccine design for high-level CD8+ T cell responses.”
A presentation of the vaccine technology will be given by Richard S. Kornbluth, MD, PhD, Multimeric’s President and Chief Scientific Officer in a session entitled, “Cellular and Molecular Mechanisms of Vaccines for Enhancing Protective Immune Responses.” The presentation will be on Monday, May 13, 2019, 10:30 AM – 10:45 AM, Room 25ABC, San Diego Convention Center.
The Company will also present poster P1628 on Sunday, May 12, 2019, 2:30 PM – 3:45 PM, in the Exhibit/Poster Hall.
A link to the poster can be found here.